Ina M. Jürgenliemk-Schulz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ina M. Jürgenliemk-Schulz has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Astrid A.C. de Leeuw
Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands
4 shared publicationsChristel N. Nomden
Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands
3 shared publications- Barbara Segedin
Department of Radiotherapy, Institute of Oncology Ljubljana and Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
2 shared publications - Bhavana Rai
Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 shared publications Cornelis G. Gerestein
Department of Gynecologic Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2 shared publications- Cyrus Chargari
Radiation Oncology Department, centre hospitalier universitaire Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, Sorbonne Université, Paris, France
2 shared publications
Latest Publications
- Open Access
- 17 December 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 57, 101098
Dosimetric comparison between brachytherapy and MR-Linac as a boost modality for locally advanced cervical cancer
- 17 December 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 57, 101098
Open AccessDosimetric comparison between brachytherapy and MR-Linac as a boost modality for locally advanced cervical cancer
- Open Access
- 30 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 181, 109501
Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
- 30 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 181, 109501
Open AccessAssociation of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
- Open Access
- 30 May 2022
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 35, 97-103
The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis
- 30 May 2022
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 35, 97-103
Open AccessThe impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis
- 14 March 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 165 (2) , 339-346
Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study
- 14 March 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 165 (2) , 339-346
Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study
- Open Access
Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists
Background: There are various society-specific guidelines addressing adjuvant brachytherapy (BT) after surgery for endometrial cancer (EC). However, these recommendations are not uniform. Against this background, clinicians need to make decisions despite gaps between best scientific evidence and clinical practice. We explored factors influencing decision-making for adjuvant BT in clinical routine among experienced European radiation oncologists in the field of gynaecological radiotherapy (RT). We also investigated the dose and technique of BT. Methods: Nineteen European experts for gynaecological BT selected by the Groupe Européen de Curiethérapie and the European Society for Radiotherapy & Oncology provided their decision criteria and technique for postoperative RT in EC. The decision criteria were captured and converted into decision trees, and consensus and dissent were evaluated based on the objective consensus methodology. Results: The decision criteria used by the experts were tumour extension, grading, nodal status, lymphovascular invasion, and cervical stroma/vaginal invasion (yes/no). No expert recommended adjuvant BT for pT1a G1-2 EC without substantial LVSI. Eighty-four percent of experts recommended BT for pT1a G3 EC without substantial LVSI. Up to 74% of experts used adjuvant BT for pT1b LVSI-negative and pT2 G1–2 LVSI-negative disease. For 74–84% of experts, EBRT + BT was the treatment of choice for nodal-positive pT2 disease and for pT3 EC with cervical/vaginal invasion. For all other tumour stages, there was no clear consensus for adjuvant treatment. Four experts already used molecular markers for decision-making. Sixty-five percent of experts recommended fractionation regimens of 3 × 7 Gy or 4 × 5 Gy for BT as monotherapy and 2 × 5 Gy for combination with EBRT. The most commonly used applicator for BT was a vaginal cylinder; 82% recommended image-guided BT. Conclusions: There was a clear trend towards adjuvant BT for stage IA G3, stage IB, and stage II G1–2 LVSI-negative EC. Likewise, there was a non-uniform pattern for BT dose prescription but a clear trend towards 3D image-based BT. Finally, molecular characteristics were already used in daily decision-making by some experts under the pretext that upcoming trials will bring more clarity to this topic.
Open AccessRole of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists
Background: There are various society-specific guidelines addressing adjuvant brachytherapy (BT) after surgery for endometrial cancer (EC). However, these recommendations are not uniform. Against this background, clinicians need to make decisions despite gaps between best scientific evidence and clinical practice. We explored factors influencing decision-making for adjuvant BT in clinical routine among experienced European radiation oncologists in the field of gynaecological radiotherapy (RT). We also investigated the dose and technique of BT. Methods: Nineteen European experts for gynaecological BT selected by the Groupe Européen de Curiethérapie and the European Society for Radiotherapy & Oncology provided their decision criteria and technique for postoperative RT in EC. The decision criteria were captured and converted into decision trees, and consensus and dissent were evaluated based on the objective consensus methodology. Results: The decision criteria used by the experts were tumour extension, grading, nodal status, lymphovascular invasion, and cervical stroma/vaginal invasion (yes/no). No expert recommended adjuvant BT for pT1a G1-2 EC without substantial LVSI. Eighty-four percent of experts recommended BT for pT1a G3 EC without substantial LVSI. Up to 74% of experts used adjuvant BT for pT1b LVSI-negative and pT2 G1–2 LVSI-negative disease. For 74–84% of experts, EBRT + BT was the treatment of choice for nodal-positive pT2 disease and for pT3 EC with cervical/vaginal invasion. For all other tumour stages, there was no clear consensus for adjuvant treatment. Four experts already used molecular markers for decision-making. Sixty-five percent of experts recommended fractionation regimens of 3 × 7 Gy or 4 × 5 Gy for BT as monotherapy and 2 × 5 Gy for combination with EBRT. The most commonly used applicator for BT was a vaginal cylinder; 82% recommended image-guided BT. Conclusions: There was a clear trend towards adjuvant BT for stage IA G3, stage IB, and stage II G1–2 LVSI-negative EC. Likewise, there was a non-uniform pattern for BT dose prescription but a clear trend towards 3D image-based BT. Finally, molecular characteristics were already used in daily decision-making by some experts under the pretext that upcoming trials will bring more clarity to this topic.
- Open Access
- 1 May 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 134, 185-190
Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort
- 1 May 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 134, 185-190
Open AccessNodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort
- Open Access
- 5 April 2018
- Published by Springer Nature in Cureus
- Vol. 10 (4) , e2431
Evaluation of Online Plan Adaptation Strategies for the 1.5T MR-linac Based on “First-In-Man” Treatments
The superior soft tissue contrast provided by magnetic resonance (MR) images on the 1.5T MR-linac allows for the incorporation of patient anatomy information. In this retrospective case study, we present the simulated dosimetric effects and timings of full online replanning as compared to the five plan adaptation methods currently available on the 1.5T MR-linac treatment system. For this case, it is possible to create treatment plans with all six methods within a time slot suitable for an online treatment procedure. However, large dosimetric differences between the plan adaptation methods and full online replanning are present with regards to target coverage and dose to organs at risk (OARs).
- 5 April 2018
- Published by Springer Nature in Cureus
- Vol. 10 (4) , e2431
Open AccessEvaluation of Online Plan Adaptation Strategies for the 1.5T MR-linac Based on “First-In-Man” Treatments
The superior soft tissue contrast provided by magnetic resonance (MR) images on the 1.5T MR-linac allows for the incorporation of patient anatomy information. In this retrospective case study, we present the simulated dosimetric effects and timings of full online replanning as compared to the five plan adaptation methods currently available on the 1.5T MR-linac treatment system. For this case, it is possible to create treatment plans with all six methods within a time slot suitable for an online treatment procedure. However, large dosimetric differences between the plan adaptation methods and full online replanning are present with regards to target coverage and dose to organs at risk (OARs).
- 1 June 2014
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 111 (3) , 442-445
Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer
- 1 June 2014
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 111 (3) , 442-445
Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer